Concr’s AI-VISION was recently featured in the Department for Science, Innovation and Technology’s press release* announcing the six projects funded by Innovate UK and the Office for Life Sciences to improve patient outcomes by developing innovative technologies to enable faster, safer and more accurate diagnosis, and direct patients towards the most appropriate treatments.
With reference to the recent Darzi Review that laid bare the fact that the cancer survival rates in England are lagging far behind other countries, the announcement emphasised the potential of breakthrough technologies like Concr’s FarrSight®-Twin to give new hope to patients and to become commercial successes.
Earlier this year in July, Concr announced the launch of its observational clinical study, VISION, evaluating Concr’s therapeutic response predictive algorithm to define biomarkers of chemotherapy and immunotherapy response in early Triple Negative Breast Cancer (TNBC). As of October, the study deploying the FarrSight®-Twin technology to create a “digital twin” of every individual patient to predict treatment response is rapidly nearing to achieve its enrolment target of 200 patients.
To learn more about FarrSight®-Twin: https://concr.co/news/digital-twin
To explore how you can partner with Concr: irina@concr.co
For media inquiries, interviews, or further information about Concr, please contact:
Emre Misirlioglu
info@concr.co
* Department for Science, Innovation and Technology. (2024, October 6). New government tech deals boost the business of cancer detection [Press release]. https://www.gov.uk/government/...
